Интегральная оценка параметров повторной трансректальной мультифокальной биопсии в диагностике рака предстательной железы

1. Landis S.H., Murray T., Bolden S., Wingo P.A. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 31: 8–31.

2. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М.; 1999. с. 5.

3. Djavan B., Zlotta A.R., Remzi M. et al. Optimal predictors of prostate cancer in repeat prostate biopsy: a prospective study in 1051 men. J Urol 2000; 163(4): 1144–8.

4. Seidman H., Mushinski M.H., Gelb S.K., Silverberg E. Probabilities of eventually developing or dying of cancer in United States 1985. CA Cancer J Clin 1985; 35: 36–56.

5. Morgan T.O., McLeod D.G., Leifer E.S. et al. Prospective use of free prostate-specific antigen to avoid repeat prostate biopsies in men with elevated total prostate-specific antigen. Urology 1996; 48: 76–80.

6. Djavan B., Remzi M., Marberger M. When and how a prostatic rebiopsy should be performed? Eur Urol Suppl 2002;1 (6): 52–9.

7. Hendrikx A., Safarik L., Hammerer P. TRUS and biopsy: practical aspects. Eur Urol 2002; 41(6): 1–10.

8. Gretzer M.B., Partin A.W. PSA levels and the probability of prostate cancer on biopsy. Eur Urol Suppl 2002; 1 (6): 21–7.